This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
Diagnosis of AML according to WHO (2022) or ICC criteria.
Age ≥55 and ≤75 years.
ECOG performance status score of 0-2.
Total bilirubin ≤1.5× upper limit of normal (ULN)
Acute promyelocytic leukemia with PML-RARA fusion gene.
AML with RUNX1-RUNX1T1 or CBFB-MYH11 fusion genes.
AML with BCR-ABL fusion gene.
Relapsed or refractory AML (previously treated with induction chemotherapy, but hydroxyurea is allowed).
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor